Metformin is an US FDA-approved drug that is currently a first-line treatment for type 2 diabetes. It is currently under investigation as a TB/HIV host-directed therapy in a Phase II open-label study at Aurum Institute.
Metformin treatment has shown to reduce tissue pathology and inflammatory cytokines in mice (Singhal et al. Sci Translat Med 2014)